On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

Wave Life Sciences stock sinks as Phase 1 data for obesity drug disappoints investors. But Oppenheimer still recommends ...

Read about the new Biocom Octane partnership. Discover how this collaboration expands capital and accelerator access for ...

Achieve exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H ...

With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its ...

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based ...

Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007 ...

Wave Life Sciences (NASDAQ:WVE) shares are trading near historic lows after two Wall Street firms cut their price targets ...

Despite world-class AI-biotech research, a Nobel Prize-winning protein design lab and proximity to global AI expertise, ...

In life sciences, enterprise value only emerges when generative AI is treated as a business capability and embedded into ...

Rhode Island is building momentum in the life science sector, and I believe Will is well-positioned to take it to the next ...